Levetiracetam (Keppra) vs Levetiracetam (Keppra XR)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Synaptic vesicle protein 2A (SV2A) · full Epilepsy pipeline
Levetiracetam (Keppra)
Marketed by UCB
NCT00150709 · Phase 3 · completed
This was a non-randomized, open-label extension study in which all children continued on levetiracetam after completing earlier pediatric levetiracetam trials. It reports descriptive seizure-frequency changes (e.g., median ~66% reduction in partial seizures among prior placebo-treated patients) over roughly two years, but with no control group and no formal statistical comparison. Because it is a genuine roll-over of previously randomized trial participants, it offers real longitudinal data but only moderate-strength evidence.
Next expected readout: February 2029 · NCT07130786 (registry estimate)
Reported efficacy
Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period (During the Treatment Period (an average of 2 years), compared to Baseline); Percentage Change From Baseline in Total (Type I, II, III) Seizure Frequency Per Week Over Time During the Treatment Period (During the Treatment Period (an average of 2 years), compared to Baseline): Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period (During the Treatment Period (an average of 2 years), compared to Baseline): N159 PBO/LEV -66.4 percentage of change (IQR -90 to -22.3) | N159 LEV/LEV -47.8 percentage of change (IQR -76.2 to -25.4) | N01010+N151 LEV/LEV -66.4 percentage of change (IQR -93.6 to -5.6) (not_applicable)
Result source: NCT00150709
Levetiracetam (Keppra XR)
Marketed by UCB
NCT00419094 · Phase 3 · completed
This randomized, triple-blind Phase 3 trial assigned 228 participants with partial-onset seizures to Keppra XR 2000 mg/day or 1000 mg/day in a 3:1 ratio during conversion to monotherapy. The primary endpoint was the cumulative rate of seizure-related exit at Day 112, tested in the 2000 mg/day group only against a historical control rate of 0.678. The exit rate was 0.375 (95% CI 0.297 to 0.453), so the prespecified criterion was met; the comparison relied on a historical benchmark because the trial had no concurrent placebo or active control arm.
Reported efficacy
The Cumulative Exit Rate at 112 Days After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase: The Cumulative Exit Rate at 112 Days After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase (112 days): Keppra XR 2000 mg/Day 37.5% (95% CI 29.7% to 45.3%) (met)
Result source: NCT00419094
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Levetiracetam (Keppra) | Levetiracetam (Keppra XR) |
|---|---|---|
| Seizure frequency, % change | —Not posted · NCT00160550 | —Not reported |
| 50% responder rate | —Not posted · NCT00160550 | —Not reported |
| Seizure freedom | —Not posted · NCT00160550 | —Not reported |
Seizure frequency, % change
- Levetiracetam (Keppra)
- —Not posted · NCT00160550
- Levetiracetam (Keppra XR)
- —Not reported
50% responder rate
- Levetiracetam (Keppra)
- —Not posted · NCT00160550
- Levetiracetam (Keppra XR)
- —Not reported
Seizure freedom
- Levetiracetam (Keppra)
- —Not posted · NCT00160550
- Levetiracetam (Keppra XR)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Levetiracetam (Keppra): 4 of 4 rows · Levetiracetam (Keppra XR): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Levetiracetam (Keppra) | Levetiracetam (Keppra XR) |
|---|---|---|
| Dropout rate | 58.5%N01010+N151 LEV/LEVa NCT00150709 · Phase 3 · monotherapy show 32 more results57.1%N01052 LEV/LEV NCT00150709 · Phase 3 · monotherapy 69.7%N159 LEV/LEV NCT00150709 · Phase 3 · monotherapy 69.6%N159 PBO/LEV NCT00150709 · Phase 3 · monotherapy 15.6%Levetiracetam: Adjunctive Therapy NCT03340064 · Phase 3 · combination 0%Levetiracetam: Monotherapy NCT03340064 · Phase 3 · monotherapy 37.3% NCT01229735 · Phase 4 · registry result, not featured evidence — NCT00855738 · Phase 4 · registry result, not featured evidence 38.2% NCT00510783 · Phase 4 · registry result, not featured evidence 33.3% NCT01318408 · Phase 4 · registry result, not featured evidence 13.1% NCT00160654 · Phase 4 · registry result, not featured evidence — NCT01398956 · Phase 3 · registry result, not featured evidence — NCT01954121 · Phase 3 · registry result, not featured evidence 70%3000 mg/Day NCT01506882 · Phase 3 · registry result, not featured evidence 36.1%1000 mg/Day to 2000 mg/Day NCT01506882 · Phase 3 · registry result, not featured evidence 25% NCT01345058 · Phase 3 · registry result, not featured evidence · combination 35.7% NCT01228747 · Phase 3 · registry result, not featured evidence 15.1% NCT01063764 · Phase 3 · registry result, not featured evidence 15.4% NCT01292837 · Phase 3 · registry result, not featured evidence — NCT00367432 · Phase 3 · registry result, not featured evidence 29.4% NCT00152516 · Phase 3 · registry result, not featured evidence 11.5% NCT00291655 · Phase 3 · registry result, not featured evidence 27.3% NCT00150813 · Phase 3 · registry result, not featured evidence 44.6%N165 Randomized Treatment LEV NCT00160615 · Phase 3 · registry result, not featured evidence —N165 Randomized Treatment LEV (FAS NCT00160615 · Phase 3 · registry result, not featured evidence 4.3% NCT01982812 · Phase 2 · registry result, not featured evidence 0% NCT01407523 · Phase 2 · registry result, not featured evidence 15.8% NCT00505934 · Phase 2 · registry result, not featured evidence 0% NCT00535392 · Phase 2 · registry result, not featured evidence 10.6% NCT01463033 · Phase 2 · registry result, not featured evidence 6.3% NCT01720667 · Phase 1/2 · registry result, not featured evidence 0%High Dose NCT00884052 · Phase 1/2 · registry result, not featured evidence 0%Low Dose NCT00884052 · Phase 1/2 · registry result, not featured evidence | 17.5%2000 mg/daya NCT00419094 · Phase 3 show 5 more results12.3%1000 mg/day NCT00419094 · Phase 3 10.1% NCT00368069 · Phase 3 12.6% NCT00419393 · Phase 3 · registry result, not featured evidence 0%Keppra XR in Adults (18-55 Years O NCT00961441 · Phase 2 · registry result, not featured evidence 0%Keppra XR in Children (12-16 Years NCT00961441 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 4.9%N01010+N151 LEV/LEVa NCT00150709 · Phase 3 · monotherapy show 32 more results21.4%N01052 LEV/LEV NCT00150709 · Phase 3 · monotherapy 2.2%N159 LEV/LEV NCT00150709 · Phase 3 · monotherapy 10.1%N159 PBO/LEV NCT00150709 · Phase 3 · monotherapy 6.3%Levetiracetam: Adjunctive Therapy NCT03340064 · Phase 3 · combination 0%Levetiracetam: Monotherapy NCT03340064 · Phase 3 · monotherapy — NCT01229735 · Phase 4 · registry result, not featured evidence — NCT00855738 · Phase 4 · registry result, not featured evidence — NCT00510783 · Phase 4 · registry result, not featured evidence — NCT01318408 · Phase 4 · registry result, not featured evidence 5.6% NCT00160654 · Phase 4 · registry result, not featured evidence — NCT01398956 · Phase 3 · registry result, not featured evidence — NCT01954121 · Phase 3 · registry result, not featured evidence —3000 mg/Day NCT01506882 · Phase 3 · registry result, not featured evidence —1000 mg/Day to 2000 mg/Day NCT01506882 · Phase 3 · registry result, not featured evidence — NCT01345058 · Phase 3 · registry result, not featured evidence · combination 3.2% NCT01228747 · Phase 3 · registry result, not featured evidence 5.5% NCT01063764 · Phase 3 · registry result, not featured evidence 7.7% NCT01292837 · Phase 3 · registry result, not featured evidence — NCT00367432 · Phase 3 · registry result, not featured evidence 7.1% NCT00152516 · Phase 3 · registry result, not featured evidence — NCT00291655 · Phase 3 · registry result, not featured evidence 1.5% NCT00150813 · Phase 3 · registry result, not featured evidence 11.9%N165 Randomized Treatment LEV NCT00160615 · Phase 3 · registry result, not featured evidence —N165 Randomized Treatment LEV (FAS NCT00160615 · Phase 3 · registry result, not featured evidence 0% NCT01982812 · Phase 2 · registry result, not featured evidence — NCT01407523 · Phase 2 · registry result, not featured evidence 5.3% NCT00505934 · Phase 2 · registry result, not featured evidence — NCT00535392 · Phase 2 · registry result, not featured evidence — NCT01463033 · Phase 2 · registry result, not featured evidence 1.6% NCT01720667 · Phase 1/2 · registry result, not featured evidence —High Dose NCT00884052 · Phase 1/2 · registry result, not featured evidence —Low Dose NCT00884052 · Phase 1/2 · registry result, not featured evidence | 4.1%2000 mg/daya NCT00419094 · Phase 3 show 5 more results5.3%1000 mg/day NCT00419094 · Phase 3 6.3% NCT00368069 · Phase 3 2.6% NCT00419393 · Phase 3 · registry result, not featured evidence —Keppra XR in Adults (18-55 Years O NCT00961441 · Phase 2 · registry result, not featured evidence —Keppra XR in Children (12-16 Years NCT00961441 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 29.3%N01010+N151 LEV/LEVa NCT00150709 · Phase 3 · monotherapy show 32 more results50%N01052 LEV/LEV NCT00150709 · Phase 3 · monotherapy 39.3%N159 LEV/LEV NCT00150709 · Phase 3 · monotherapy 25.3%N159 PBO/LEV NCT00150709 · Phase 3 · monotherapy 56.3%Levetiracetam: Adjunctive Therapy NCT03340064 · Phase 3 · combination 33.3%Levetiracetam: Monotherapy NCT03340064 · Phase 3 · monotherapy 5.6% NCT01229735 · Phase 4 · registry result, not featured evidence 0% NCT00855738 · Phase 4 · registry result, not featured evidence 0% NCT00510783 · Phase 4 · registry result, not featured evidence 0% NCT01318408 · Phase 4 · registry result, not featured evidence 6% NCT00160654 · Phase 4 · registry result, not featured evidence 29.5% NCT01398956 · Phase 3 · registry result, not featured evidence 4.1% NCT01954121 · Phase 3 · registry result, not featured evidence 20%3000 mg/Day NCT01506882 · Phase 3 · registry result, not featured evidence 13.1%1000 mg/Day to 2000 mg/Day NCT01506882 · Phase 3 · registry result, not featured evidence 0% NCT01345058 · Phase 3 · registry result, not featured evidence · combination 0.8% NCT01228747 · Phase 3 · registry result, not featured evidence 11% NCT01063764 · Phase 3 · registry result, not featured evidence 0% NCT01292837 · Phase 3 · registry result, not featured evidence 16.1% NCT00367432 · Phase 3 · registry result, not featured evidence 18% NCT00152516 · Phase 3 · registry result, not featured evidence 4.6% NCT00291655 · Phase 3 · registry result, not featured evidence 6.1% NCT00150813 · Phase 3 · registry result, not featured evidence —N165 Randomized Treatment LEV NCT00160615 · Phase 3 · registry result, not featured evidence 21.8%N165 Randomized Treatment LEV (FAS NCT00160615 · Phase 3 · registry result, not featured evidence 21.7% NCT01982812 · Phase 2 · registry result, not featured evidence 0% NCT01407523 · Phase 2 · registry result, not featured evidence 21.1% NCT00505934 · Phase 2 · registry result, not featured evidence 9.1% NCT00535392 · Phase 2 · registry result, not featured evidence 27.3% NCT01463033 · Phase 2 · registry result, not featured evidence 1.6% NCT01720667 · Phase 1/2 · registry result, not featured evidence —High Dose NCT00884052 · Phase 1/2 · registry result, not featured evidence —Low Dose NCT00884052 · Phase 1/2 · registry result, not featured evidence | 7%2000 mg/daya NCT00419094 · Phase 3 show 5 more results3.5%1000 mg/day NCT00419094 · Phase 3 7.8% NCT00368069 · Phase 3 11.6% NCT00419393 · Phase 3 · registry result, not featured evidence 0%Keppra XR in Adults (18-55 Years O NCT00961441 · Phase 2 · registry result, not featured evidence 0%Keppra XR in Children (12-16 Years NCT00961441 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 28 more resultsnasopharyngitis 83.3% epistaxis 50% hand-foot-and-mouth disease 50% NCT03340064 · Phase 3 · monotherapy somnolence 20.3% dizziness 16.9% nasopharyngitis 13.6% NCT01229735 · Phase 4 · registry result, not featured evidence somnolence 7.5% weight increased 5% dizziness 2.5% NCT00855738 · Phase 4 · registry result, not featured evidence dizziness 9.2% fatigue 9.2% burning at the iv site 6.6% NCT00510783 · Phase 4 · registry result, not featured evidence fatigue 16.7% NCT01318408 · Phase 4 · registry result, not featured evidence somnolence 29.9% dizziness 14.3% headache 6.4% NCT00160654 · Phase 4 · registry result, not featured evidence nasopharyngitis 79.5% convulsion 36.4% dental caries 25% NCT01398956 · Phase 3 · registry result, not featured evidence nasopharyngitis 18.3% dizziness 15.1% somnolence 9.2% NCT01954121 · Phase 3 · registry result, not featured evidence 3000 mg/Day nasopharyngitis 40% diarrhoea 20% head injury 20% NCT01506882 · Phase 3 · registry result, not featured evidence 1000 mg/Day to 2000 mg/Day nasopharyngitis 77% somnolence 41% malaise 19.7% NCT01506882 · Phase 3 · registry result, not featured evidence erectile dysfunction 11.1% fatigue 11.1% memory/cognitive difficulties/confusion 11.1% NCT01345058 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 19% (placebo 16%) protein urine present 7.9% (placebo 0.8%) platelet count decreased 5.6% (placebo 3.2%) NCT01228747 · Phase 3 · registry result, not featured evidence nasopharyngitis 74% somnolence 46.6% influenza 27.4% NCT01063764 · Phase 3 · registry result, not featured evidence convulsion 23.1% nasopharyngitis 23.1% somnolence 23.1% NCT01292837 · Phase 3 · registry result, not featured evidence nasopharyngitis 77.4% somnolence 39.9% contusion 27.6% NCT00367432 · Phase 3 · registry result, not featured evidence pyrexia 31.8% upper respiratory tract infection 24.3% vomiting 16.1% NCT00152516 · Phase 3 · registry result, not featured evidence weight increased 5.4% weight decreased 2.3% NCT00291655 · Phase 3 · registry result, not featured evidence nasopharyngitis 75.2% (placebo 76%) contusion 28.7% (placebo 32%) headache 27.7% (placebo 32%) NCT00160615 · Phase 3 · registry result, not featured evidence increased potassium 30.4% increased phosphate 26.1% increased ast 21.7% NCT01982812 · Phase 2 · registry result, not featured evidence arthralgia 6.3% contusion 6.3% gingivitis 6.3% NCT01407523 · Phase 2 · registry result, not featured evidence hypotension 10.5% pyrexia 10.5% bradycardia 5.3% NCT00505934 · Phase 2 · registry result, not featured evidence convulsion 9.1% dry mouth 9.1% hypotension 9.1% NCT00535392 · Phase 2 · registry result, not featured evidence fatigue 42.4% headache 42.4% drowsiness 30.3% NCT01463033 · Phase 2 · registry result, not featured evidence vasopressor requirement 15.6% respiratory abnormality 12.5% sedation 10.9% NCT01720667 · Phase 1/2 · registry result, not featured evidence | show 5 more resultsinfluenza 7.8% (placebo 3.8%) somnolence 7.8% (placebo 2.5%) headache 6.5% (placebo 13.9%) NCT00368069 · Phase 3 headache 13.8% nasopharyngitis 7.9% somnolence 7.9% NCT00419393 · Phase 3 · registry result, not featured evidence arthralgia 7.7% dysmenorrhoea 7.7% hypoaesthesia facial 7.7% NCT00961441 · Phase 2 · registry result, not featured evidence abnormal behaviour 8.3% fatigue 8.3% lymphadenopathy 8.3% NCT00961441 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Levetiracetam (Keppra)
show 5 more results
show 5 more results
show 3 more results
show 43 more results
show 3 more results
+ 45 further endpoints in the CSV export.
Levetiracetam (Keppra XR)
show 1 more result
show 1 more result
show 1 more result
Focal Onset Seizures
Shared mechanism: Synaptic vesicle protein 2A (SV2A) · full Focal Onset Seizures pipeline
Levetiracetam (Keppra)
Marketed by UCB
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Levetiracetam (Keppra XR)
Marketed by UCB
NCT00419094 · Phase 3 · completed
This randomized, triple-blind Phase 3 trial assigned 228 participants with partial-onset seizures to Keppra XR 2000 mg/day or 1000 mg/day in a 3:1 ratio during conversion to monotherapy. The primary endpoint was the cumulative rate of seizure-related exit at Day 112, tested in the 2000 mg/day group only against a historical control rate of 0.678. The exit rate was 0.375 (95% CI 0.297 to 0.453), so the prespecified criterion was met; the comparison relied on a historical benchmark because the trial had no concurrent placebo or active control arm.
Reported efficacy
The Cumulative Exit Rate at 112 Days After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase: The Cumulative Exit Rate at 112 Days After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase (112 days): Keppra XR 2000 mg/Day 37.5% (95% CI 29.7% to 45.3%) (met)
Result source: NCT00419094
Results for Focal Onset Seizures
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
Coverage. Levetiracetam (Keppra): 4 of 4 rows · Levetiracetam (Keppra XR): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Levetiracetam (Keppra) | Levetiracetam (Keppra XR) |
|---|---|---|
| Dropout rate | 37.3%a NCT01229735 · Phase 4 · registry result, not featured evidence show 9 more results— NCT00855738 · Phase 4 · registry result, not featured evidence — NCT01954121 · Phase 3 · registry result, not featured evidence 70%3000 mg/Day NCT01506882 · Phase 3 · registry result, not featured evidence 36.1%1000 mg/Day to 2000 mg/Day NCT01506882 · Phase 3 · registry result, not featured evidence — NCT00367432 · Phase 3 · registry result, not featured evidence 29.4% NCT00152516 · Phase 3 · registry result, not featured evidence 44.6%N165 Randomized Treatment LEV NCT00160615 · Phase 3 · registry result, not featured evidence —N165 Randomized Treatment LEV (FAS NCT00160615 · Phase 3 · registry result, not featured evidence 0% NCT01407523 · Phase 2 · registry result, not featured evidence | 17.5%2000 mg/daya NCT00419094 · Phase 3 show 1 more result12.3%1000 mg/day NCT00419094 · Phase 3 |
| Discontinued due to AEs | —a NCT01229735 · Phase 4 · registry result, not featured evidence show 9 more results— NCT00855738 · Phase 4 · registry result, not featured evidence — NCT01954121 · Phase 3 · registry result, not featured evidence —3000 mg/Day NCT01506882 · Phase 3 · registry result, not featured evidence —1000 mg/Day to 2000 mg/Day NCT01506882 · Phase 3 · registry result, not featured evidence — NCT00367432 · Phase 3 · registry result, not featured evidence 7.1% NCT00152516 · Phase 3 · registry result, not featured evidence 11.9%N165 Randomized Treatment LEV NCT00160615 · Phase 3 · registry result, not featured evidence —N165 Randomized Treatment LEV (FAS NCT00160615 · Phase 3 · registry result, not featured evidence — NCT01407523 · Phase 2 · registry result, not featured evidence | 4.1%2000 mg/daya NCT00419094 · Phase 3 show 1 more result5.3%1000 mg/day NCT00419094 · Phase 3 |
| Serious AEs | 5.6%a NCT01229735 · Phase 4 · registry result, not featured evidence show 9 more results0% NCT00855738 · Phase 4 · registry result, not featured evidence 4.1% NCT01954121 · Phase 3 · registry result, not featured evidence 20%3000 mg/Day NCT01506882 · Phase 3 · registry result, not featured evidence 13.1%1000 mg/Day to 2000 mg/Day NCT01506882 · Phase 3 · registry result, not featured evidence 16.1% NCT00367432 · Phase 3 · registry result, not featured evidence 18% NCT00152516 · Phase 3 · registry result, not featured evidence —N165 Randomized Treatment LEV NCT00160615 · Phase 3 · registry result, not featured evidence 21.8%N165 Randomized Treatment LEV (FAS NCT00160615 · Phase 3 · registry result, not featured evidence 0% NCT01407523 · Phase 2 · registry result, not featured evidence | 7%2000 mg/daya NCT00419094 · Phase 3 show 1 more result3.5%1000 mg/day NCT00419094 · Phase 3 |
| Most frequent reported AEs | a somnolence 20.3% dizziness 16.9% nasopharyngitis 13.6% NCT01229735 · Phase 4 · registry result, not featured evidence show 8 more resultssomnolence 7.5% weight increased 5% dizziness 2.5% NCT00855738 · Phase 4 · registry result, not featured evidence nasopharyngitis 18.3% dizziness 15.1% somnolence 9.2% NCT01954121 · Phase 3 · registry result, not featured evidence 3000 mg/Day nasopharyngitis 40% diarrhoea 20% head injury 20% NCT01506882 · Phase 3 · registry result, not featured evidence 1000 mg/Day to 2000 mg/Day nasopharyngitis 77% somnolence 41% malaise 19.7% NCT01506882 · Phase 3 · registry result, not featured evidence nasopharyngitis 77.4% somnolence 39.9% contusion 27.6% NCT00367432 · Phase 3 · registry result, not featured evidence pyrexia 31.8% upper respiratory tract infection 24.3% vomiting 16.1% NCT00152516 · Phase 3 · registry result, not featured evidence nasopharyngitis 75.2% (placebo 76%) contusion 28.7% (placebo 32%) headache 27.7% (placebo 32%) NCT00160615 · Phase 3 · registry result, not featured evidence arthralgia 6.3% contusion 6.3% gingivitis 6.3% NCT01407523 · Phase 2 · registry result, not featured evidence | show 1 more result |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Levetiracetam (Keppra)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 10 further endpoints in the CSV export.
Levetiracetam (Keppra XR)
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Levetiracetam (Keppra)'s landscape · Levetiracetam (Keppra XR)'s landscape